Some disease areas bucked the trend of shrinking pipelines, however, with immune and cardiovascular indications seeing an ...

The number of drugs in development has fallen for the first time since the mid-1990s, according to a Citeline report. | The ...

Curanex Pharmaceuticals, Inc. CURX on Thursday said it is expanding its drug development pipeline. Pipeline Expansion Adds ...

Early-stage drug development worldwide has nearly doubled over the past decade and shifted from a U.S.-dominated model to a ...

The recent uptick in IPOs is an encouraging signal after a drought for much of 2025. Experts point to AI as a driving force ...

OPKO Health has improved its financial position by selling most of BioReference, reducing cash burn, and strengthening its balance sheet. Ngenla's profit share with Pfizer has underperformed ...

Curanex believes the combination of major unmet need, limited treatment options and growing clinical recognition supports a ...

DelveInsight’s, “Hepatic Tumor Pipeline Insight 2026” report provides comprehensive insights about 75+ companies and ...

We explore what allosteric modulators are, their benefits and drawbacks, and which candidates are currently advancing through ...

Systemic Lupus Erythematosus Clinical Trial Pipeline Accelerates as 120+ Pharma Companies Rigorously Developing Drugs for Market Entry | DelveInsight The SLE clinical trial analysis report delivers ...

OPKO Health is refocusing on drug development, with most pipeline assets in early stages and limited near-term catalysts.

Demand for these drugs is high, and analysts predict the market will reach nearly $100 billion by the end of the decade. And ...